With Chinese New Year around the corner, the rush is on to bring as many COVID treatments to the market as possible, given the probability of an enormous spike in infections. Among those stepping up, a Nanjing company is joining the US heavyweights.
As the many millions head home to then return again over the coming weeks, Chinese authorities are seeking to ramp up production of localised COVID treatments, with a focus on protecting high-risk groups.
随着数百万人回国并在未来几周内再次返回，中国当局正在寻求增加本地化新冠治疗药物的生产，重点是保护高危人群。
Nanjing-based firm, Simcere, is among the companies preparing to produce drugs. Their SIM0417 is jointly developed with the Shanghai Institute of Materia Medica and the Wuhan Institute of Virology.
南京公司先声药业是准备生产药品的公司之一。他们的SIM0417是与上海药物研究所和武汉病毒研究所联合开发的。
The Global Times reported yesterday that Simcere will centre production of SIM0417 both here in Nanjing and on the southern island province of Hainan.
《环球时报》昨天报道称，先声药业将在南京和南部岛屿省份海南集中生产 SIM0417。
Dating back to 1995, Simcere operates under the slogan, “Providing today’s patients with medicines of the future”. The company, based on Xuanwu Avenue in Nanjing, has established R&D centres in both not-so-far-away Shanghai, and Boston, USA.
先声药业的历史可以追溯到1995年，其经营口号是“为今天的患者提供未来的药物”。该公司总部位于南京玄武大道，在不远的上海和美国波士顿均设有研发中心。
And also from America to the localised-COVID-drug-production merry go round in China comes Pfizer. Its famed Paxlovid will reportedly be available in the coming months.
同样从美国到中国本地化的新冠药物生产旋转木马的还有辉瑞公司。据报道，其著名的 Paxlovid 将在未来几个月内上市。
Joint venture partner in China for Pfizer in the project is all-but confirmed to be Huahai Pharmaceutical, based in Linhai City of Zhejiang Province. Huahai announced earlier this week its dealings with Pfizer to accelerate localised Paxlovid production.
该项目的辉瑞在中国的合资伙伴几乎已被确认为位于浙江省临海市的华海药业。华海药业本周早些时候宣布与辉瑞公司合作，以加速 Paxlovid 的本地化生产。
While Huahai Pharmaceutical is among the five Chinese companies which are to produce a generic version of Paxlovid for low and middle-income countries, Pfizer CEO, Albert Bourla, has stated that Paxlovid for the local Chinese market would be the original version of the drug.
虽然华海药业是为低收入和中等收入国家生产 Paxlovid 仿制药的五家中国公司之一，但辉瑞首席执行官 Albert Bourla 表示，针对中国本土市场的 Paxlovid 将是该药物的原版。
Founded in 1989 and today with a staff of nearly 7,000, Huahai was the first Chinese pharmaceutical company to pass US FDA certification for ready-to-market pharmaceutical products.
华海药业成立于1989年，目前拥有员工近7000名，是第一家通过美国FDA即用药品认证的中国制药公司。
Finally to the fight comes another US drug giant; MSD (Merck Sharp & Dohme). Their COVID treatment, molnupiravir, locally produced through licensing with Sinopharm, is said to be available for purchase in China online from today.
最后，另一家美国制药巨头也加入了战斗。默沙东（默沙东）。他们的新冠治疗药物 molnupiravir 是通过国药集团许可在本地生产的，据说从今天起可以在中国网上购买。
